Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine

Cancer Research

Volumn 61, Issue 1, 2001, Pages 145-152

  Wouters, Bradly G ^a   Delahoussaye, Yvette M ^b   Evans, James W ^b   Birrell, Geoffrey W ^b   Dorie, Mary Jo ^b   Wang, Jingli ^b   Macdermed, Dhara ^b   Chiu, Roland K ^a   Martin Brown, J ^b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCIN A1; CYCLOSPORIN A; CYTOTOXIN; MANGANESE SUPEROXIDE DISMUTASE; ROTENONE; TIRAPAZAMINE; URIDINE;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; CELL KILLING; CELL MEMBRANE PERMEABILITY; CELL MEMBRANE POTENTIAL; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DOSE RESPONSE; DRUG SELECTIVITY; HYPOXIC CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL RESPIRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY CHAIN;

AEROBIOSIS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL MEMBRANE PERMEABILITY; CHO CELLS; CRICETINAE; CROSSES, GENETIC; ELECTRON TRANSPORT; HUMANS; INTRACELLULAR MEMBRANES; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MITOCHONDRIA; MITOCHONDRIA, MUSCLE; OXYGEN; SUPEROXIDE DISMUTASE; SUPEROXIDES; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0035131933     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Tumour hypoxia: The picture has changed in the 1990s
2. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: Retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a Phase I trial
3. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
4. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation
5. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours
6. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity
7. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical
8. Intranuclear metabolism of tirapazamine by matrix-associated reductases
9. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233)
10. Phase 1 trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors
11. Muscle cramping in Phase I clinical trials of tirapazamine (SR 4233) with and without radiation
12. Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks
13. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer
14. Effect of partition coefficient on the ability of nitroimidazoles to enhance the cytotoxicity of 1-(2-chloroethyl)-3-cyclo-hexyl-1-nitrosourea
15. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic Chinese hamster ovary cells overexpressing human NADPH: Cytochrome c (P-450) reductase
16. Isolation of human cell lines lacking mitochondrial DNA
17. Cell membrane potential analysis
18. Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
19. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1
20. Functional heterogeneity of an isolated mitochondrial population revealed by cytofluorometric analysis at the single organelle level
21. Isolation of subcellular organelles
22. The kinetic properties of citrate synthase from rat liver mitochondria
23. Safranine as a probe of the mitochondrial membrane potential
24. Preferential mitochondrial DNA injury caused by glucose oxidase as a steady generator of hydrogen peroxide in human fibroblasts
25. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase
26. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy
27. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential
28. Mitochondrial membrane potential monitored by JC-1 dye
29. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′tetraethyl benzimidazolcarbocyanine iodide (JC-1)
30. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin
31. Tirapazamine: Laboratory data relevant to clinical activity
32. Enzymology of tirapazamine metabolism: A review
33. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233)
34. Mitochondria and apoptosis
35. BCL-2 family members and the mitochondria in apoptosis
36. Protection against SR 4233 (Tirapazamine) aerobic cytotoxicity by the metal chelators desferrioxamine and tiron
37. Adaptation of human tumor cells to tirapazamine under aerobic conditions: Implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity
38. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes
39. Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: A 31P magnetic resonance spectroscopy study
40. Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions
41. SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cells
42. Oxidative stress, thiol reagents, and membrane potential modulate the mitochondrial permeability transition by affecting nucleotide binding to the adenine nucleotide translocase
43. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischaemia/reperfusion injury